Advertisement

help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Munshi, N. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Munshi, N. C.
The Oncologist, Vol. 6, Suppl 2, 17-21, April 2001
© 2001 AlphaMed Press


SUPPLEMENT

Arsenic Trioxide: An Emerging Therapy for Multiple Myeloma

Nikhil C. Munshi

University of Arkansas for Medical Science, Little Rock, Arkansas, USA

Correspondence: Nikhil C. Munshi, M.D., Professor of Medicine, Section of Hematology/Oncology, University of Arkansas for Medical Science, 4301 W. Markham-Slot 776, ACRC Building, Suite 916, Little Rock, Arkansas 72205, USA. Telephone: (501) 686-8250; Fax: (501) 686-6442; e-mail: Munshinikhilc{at}exchange.uams.edu

Arsenic trioxide can inhibit proliferation and induce apoptosis in multiple myeloma (MM) cells in vitro and in vivo. In addition to affecting tumor growth, arsenic trioxide has been shown to inhibit angiogenesis, suggesting that it may have significant potency in the treatment of MM. Based on these observations, the clinical efficacy of arsenic trioxide was evaluated in patients with advanced refractory MM using a fixed-dose intravenous infusion given daily for a maximum of 60 days. Nine patients were evaluable. All nine had extensive prior therapy; seven had two or more high-dose chemotherapy cycles with autologous stem cell support. All nine patients had cytogenetic abnormalities, and six had chromosome 13 deletions. Of the four patients who completed more than 30 days of arsenic trioxide infusion, two had >50% reduction in myeloma paraprotein, one had stable disease, and one progressed. Of the five patients with <30 days infusion, two had stable disease and three progressed. Thus, on an intent-to-treat basis, two of nine (23%) patients responded (>50% paraprotein reduction). The regimen was well tolerated except for development of cytopenia, which responded to G-CSF, and a grade III pulmonary complication in one patient. In summary, arsenic trioxide has activity in end-stage, high-risk myeloma and deserves further evaluation in earlier-stage disease.

Key Words. . Arsenic trioxide • Multiple myeloma • Antiangiogenesis • Apoptosis




This article has been cited by other articles:


Home page
CarcinogenesisHome page
S. A. Mousa, L. O'Connor, T. G. Rossman, and E. Block
Pro-angiogenesis action of arsenic and its reversal by selenium-derived compounds
Carcinogenesis, May 1, 2007; 28(5): 962 - 967.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Leung, A. Pang, W.-H. Yuen, Y.-L. Kwong, and E. W. C. Tse
Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells
Blood, January 15, 2007; 109(2): 740 - 746.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. A. Zykova, F. Zhu, C. Lu, L. Higgins, Y. Tatsumi, Y. Abe, A. M. Bode, and Z. Dong
Lymphokine-Activated Killer T-Cell-Originated Protein Kinase Phosphorylation of Histone H2AX Prevents Arsenite-Induced Apoptosis in RPMI7951 Melanoma Cells
Clin. Cancer Res., December 1, 2006; 12(23): 6884 - 6893.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J.-F. Gagnon, O. Bernard, L. Villeneuve, B. Tetu, and C. Guillemette
Irinotecan Inactivation Is Modulated by Epigenetic Silencing of UGT1A1 in Colon Cancer
Clin. Cancer Res., March 15, 2006; 12(6): 1850 - 1858.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
S. V. Rajkumar and R. A. Kyle
Multiple Myeloma: Diagnosis and Treatment
Mayo Clin. Proc., October 1, 2005; 80(10): 1371 - 1382.
[Abstract] [PDF]


Home page
NEJMHome page
R. A. Kyle and S. V. Rajkumar
Multiple Myeloma
N. Engl. J. Med., October 28, 2004; 351(18): 1860 - 1873.
[Full Text] [PDF]


Home page
JCOHome page
C. Aschele, D. Debernardis, S. Lonardi, R. Bandelloni, S. Casazza, S. Monfardini, and L. Gallo
Deleted in Colon Cancer Protein Expression in Colorectal Cancer Metastases: A Major Predictor of Survival in Patients With Unresectable Metastatic Disease Receiving Palliative Fluorouracil-Based Chemotherapy
J. Clin. Oncol., September 15, 2004; 22(18): 3758 - 3765.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
N. J. Bahlis, J. McCafferty-Grad, I. Jordan-McMurry, J. Neil, I. Reis, M. Kharfan-Dabaja, J. Eckman, M. Goodman, H. F. Fernandez, L. H. Boise, et al.
Feasibility and Correlates of Arsenic Trioxide Combined with Ascorbic Acid-mediated Depletion of Intracellular Glutathione for the Treatment of Relapsed/Refractory Multiple Myeloma
Clin. Cancer Res., December 1, 2002; 8(12): 3658 - 3668.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J.-F. Gagne, V. Montminy, P. Belanger, K. Journault, G. Gaucher, and C. Guillemette
Common Human UGT1A Polymorphisms and the Altered Metabolism of Irinotecan Active Metabolite 7-Ethyl-10-hydroxycamptothecin (SN-38)
Mol. Pharmacol., September 1, 2002; 62(3): 608 - 617.
[Abstract] [Full Text] [PDF]


Home page
Integr Cancer TherHome page
H. Dreher
Cancer Guide Analysis
Integr Cancer Ther, June 1, 2002; 1(2): 205 - 208.
[PDF]


Home page
The OncologistHome page
J. L. Slack, S. Waxman, G. Tricot, M. S. Tallman, and C. D. Bloomfield
Advances in the Management of Acute Promyelocytic Leukemia and Other Hematologic Malignancies with Arsenic Trioxide
Oncologist, April 1, 2002; 7(90001): 1 - 13.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
M. A. Hussein
Nontraditional Cytotoxic Therapies for Relapsed/Refractory Multiple Myeloma
Oncologist, April 1, 2002; 7(90001): 20 - 29.
[Abstract] [Full Text] [PDF]


Home page
MutagenesisHome page
G. Sciandrello, R. Barbaro, F. Caradonna, and G. Barbata
Early induction of genetic instability and apoptosis by arsenic in cultured Chinese hamster cells
Mutagenesis, March 1, 2002; 17(2): 99 - 103.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
A. J. Murgo
Clinical Trials of Arsenic Trioxide in Hematologic and Solid Tumors: Overview of the National Cancer Institute Cooperative Research and Development Studies
Oncologist, April 1, 2001; 6(90002): 22 - 28.
[Abstract] [Full Text]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2001 by AlphaMed Press.
Advertisement